Ignite Creation Date:
2024-05-06 @ 1:56 AM
Last Modification Date:
2024-10-26 @ 11:12 AM
Study NCT ID:
NCT01934647
Status:
TERMINATED
Last Update Posted:
2018-10-22
First Post:
2013-08-30
Brief Title:
Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension PAH MK-8892-003
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Non-randomized Single-Panel Open-Label Trial to Study the Safety Tolerability and Pharmacodynamics of MK-8892 Acute Dosing in Subjects With Moderate to Severe Pulmonary Arterial Hypertension
Status:
TERMINATED
Status Verified Date:
2018-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical trial will study the safety tolerability and pharmacodynamics of single doses of MK-8892 in participants with pulmonary arterial hypertension PAH The primary objective is to estimate the measured peak effect of the highest acutely tolerated HAT single oral dose of MK-8892 on pulmonary vascular resistance PVR
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MK-8892-003 | OTHER | Merck Protocol Number | None |
| 2013-001680-23 | EUDRACT_NUMBER | None | None |